The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paedi

- TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age...

Related Keywords

United States ,United Kingdom ,Zurich ,Züsz ,Switzerland ,Japan ,British ,Didier Relin ,Prnewswire Takeda ,Takeda Pharmaceutical Company Limited ,Drug Administration ,Head Of International Regulatory At Takeda ,European Commission Decision ,European Medicines Agency ,European Commission ,Takeda Pharmaceutical Company ,First Routine Prevention Treatment ,Patients Under ,New Preventative Treatment Option ,Hereditary Angioedema ,European Economic Area ,Adolescent Study ,Biologics License Application ,International Regulatory ,Commission Decision ,Open Label Phase ,Evaluate Safety ,Prevention Against Acute Attacks ,Pediatric Patients ,About Takeda Pharmaceutical ,Rare Genetics ,Plasma Derived Therapies ,Inhibitor Subcutaneous ,Medicines Agency ,Last Accessed ,Pediatric Patients Aged ,Hospital Medicine ,